Myeloid Immunosuppression in the Tumor Microenvironment Characterized by Single/Multiplex IHC

ℹ️ Arginase1 antibody mentioned in this presentation: https://cst-science.com/232p7t
ℹ️ IDO1 antibody mentioned in this presentation: https://cst-science.com/6ph27o
⬇️ Expand “Show More” to view abstract and table of contents

Infiltrating myeloid cells constitute a significant component of the suppressive tumor microenvironment (TME) and possibly contribute to therapeutic failures. An understanding of the immune regulatory context of the TME is required to harness the power of the antitumor immune response. Here, we present solutions to better understand the TME in a context-dependent manner. Using highly validated antibodies, immunohistochemical techniques are employed in a seven-color TSA-based multiplex panel along with single and dual-plex chromogenic stains to visualize biomarker expression in an array of tumor types. Thoroughly validated Arginase1 and IDO1 monoclonal antibodies add a functional readout of the immunosuppressive TME to phenotypic marker analysis.

About CST®: Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high-quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan. https://cellsignal.com/about

All trademarks are the property of their respective owners. For the most up-to-date trademark information, please visit https://www.cellsignal.com/trademarks